Approved HAE Treatments
With eight products currently approved by the FDA for preventing and treating Hereditary Angioedema (HAE) attacks, and several therapies approved for generic use, people with HAE and their physicians have options for developing an HAE treatment plan tailored to meet each person's unique needs.
ICATIBANT (GENERIC) is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of Hereditary Angioedema (HAE) in adults 18 years of age and older. Generic Icatibant is delivered by subcutaneous injection and is approved for self-administration. Multiple manufacturers offer Generic Icatibant.
Before there were approved treatments for HAE, anabolic steroids (also known as androgens) such as danazol, oxandrolone, and stanozolol were the most commonly prescribed preventive HAE therapies. While anabolic steroids have been shown to be useful, they are not well-tolerated by many women, directly linked to liver toxicity, and can cause an increase in cholesterol levels. In addition, these drugs should not be used to treat children. Research indicates that patients treated with anabolic steroids can experience breakthrough laryngeal or abdominal attacks that require hospitalization.